

**Pathkind Diagnostics Private Limited**  
**Balance Sheet as at March 31, 2019**  
**All amounts are in INR unless otherwise stated**

	Notes	As at March 31, 2019	As at March 31, 2018
<b>Equity and liabilities</b>			
<b>Shareholder's funds</b>			
Share capital	3	51,52,50,000	32,00,00,000
Reserves and surplus	4	(71,86,71,546)	(29,69,19,992)
		<b>(20,34,21,546)</b>	<b>2,30,80,008</b>
<b>Non-current liabilities</b>			
Borrowings	5	52,00,00,000	29,00,00,000
Other liabilities	6	39,20,391	11,74,870
Provisions	7	46,83,260	22,92,603
Deferred tax liabilities (net)	8	-	-
		<b>52,86,03,651</b>	<b>29,34,67,473</b>
<b>Current liabilities</b>			
Trade payables	9		
- total outstanding dues of micro enterprises and small enterprises		42,04,328	20,61,755
- total outstanding dues of creditors other than micro enterprises and small enterprises		6,83,33,377	8,19,22,591
Other liabilities	6	6,75,38,170	4,30,52,607
Provisions	7	52,80,725	61,21,937
		<b>14,53,56,600</b>	<b>13,31,58,890</b>
<b>Total</b>		<b>47,05,38,705</b>	<b>44,97,06,371</b>
<b>Assets</b>			
<b>Non-current assets</b>			
Property, Plant & Equipment			
Tangible assets	10	31,45,55,622	31,61,13,683
Intangible assets	11	2,23,98,850	2,18,10,030
Loans and advances	12	4,95,75,568	4,02,65,819
Other assets	13	19,06,696	1,45,452
		<b>38,84,36,736</b>	<b>37,83,34,984</b>
<b>Current assets</b>			
Inventories	14	3,51,81,568	3,66,67,296
Trade receivables	15	1,04,27,769	24,57,891
Cash and bank balances	16	2,28,24,436	2,67,18,371
Loans and advances	12	1,36,68,196	55,27,829
		<b>8,21,01,969</b>	<b>7,13,71,387</b>
<b>Total</b>		<b>47,05,38,705</b>	<b>44,97,06,371</b>

The accompanying notes are an integral part of these financial statements

1-33


As per our report of even date

**For Bhagi Bhardwaj Gaur & Co.**  
Chartered Accountants  
F R No.: 007895N

  
**Mohit Gupta**  
Partner  
M. No. 528337

For and on behalf of the Board of Directors

  
**Eklavya Juneja**  
(Director)  
DIN:-06754247

  
**Sanjeev Vashistha**  
(Managing Director & CEO)  
DIN:-01457971

  
**Prabhat Singh**  
(Company Secretary)  
M. No:- FCS-8724

Place: New Delhi  
Date: 25-09-2019

Place: New Delhi  
Date: 25-09-2019



**Pathkind Diagnostics Private Limited**  
**Statement of profit and loss for the year ended March 31, 2019**  
**All amounts are in INR unless otherwise stated**

	Notes	Year ended March 31, 2019	Year ended March 31, 2018
( I ) Revenue from operations	17	31,46,14,077	4,58,56,701
( II ) Other income	18	-	1,29,266
<b>( III ) Total Income</b>		<b>31,46,14,077</b>	<b>4,59,85,967</b>
<b>( IV ) Expenses</b>			
Cost of reagents, chemicals, surgicals and laboratory supplies consumed	19	13,31,90,587	4,32,92,732
Purchase of stock -in-trade		1,50,24,194	-
Employee benefit expenses	20	27,99,34,304	13,56,18,931
Depreciation and amortisation expense	21	5,07,53,811	3,23,71,164
Finance costs	22	6,79,526	1,70,761
Other expenses	23	30,20,33,209	13,13,60,274
<b>( V ) Total Expenses</b>		<b>78,16,15,631</b>	<b>34,28,13,862</b>
<b>( VI ) Profit before tax ( III - V )</b>		<b>(46,70,01,554)</b>	<b>(29,68,27,895)</b>
<b>( VII ) Tax expenses:</b>			
Current tax		-	-
Deferred tax		-	-
<b>Total tax expense</b>		<b>-</b>	<b>-</b>
<b>( VIII ) Profit for the year ( VI - VII)</b>		<b>(46,70,01,554)</b>	<b>(29,68,27,895)</b>

<b>Earnings per equity share [nominal value of share Rs. 10 (March 31, 2018: Rs. 10)]</b>	24		
<b>Basic</b>		(46.70)	(29.68)
<b>Diluted</b>		(46.70)	(29.68)

The accompanying notes are an integral part of these financial statements 1-33

As per our report of even date

**For Bhagi Bhardwaj Gaur & Co.**  
Chartered Accountants  
F.R No.: 007895N

  
**Mohit Gupta**  
Partner  
M. No. 528337

For and on behalf of the Board of Directors

  
**Eklavya Juneja**  
(Director)  
DIN:-06754247

  
**Sanjeev Vashista**  
(Managing Director & CEO)  
DIN:-01457971

  
**Prabhat Singh**  
(Company Secretary)  
M. No:- FCS-8724

Place: New Delhi  
Date: 25-09-2019

Place: New Delhi  
Date: 25-09-2019



**Pathkind Diagnostics Private Limited**  
**Cash flow statement for the year ended March 31, 2019**  
**All amounts are in INR unless otherwise stated**

	Year ended March 31, 2019	Year ended March 31, 2018
<b>A. Cash flow from operating activities</b>		
Net profit before tax	(46,70,01,554)	(29,68,27,895)
<b>Non - cash adjustments to reconcile profit before tax to net cash flows</b>		
Depreciation / amortisation	5,07,53,811	3,23,71,164
Loss on sale/ disposal of fixed assets (net)	34,35,477	63,34,798
Pre-operative expenses written off	-	14,99,250
Interest expense	6,79,526	1,70,761
<b>Operating profit before working capital changes</b>	<b>(41,21,32,740)</b>	<b>(25,64,51,921)</b>
<b>Movements in working capital:</b>		
(Increase) in trade receivables	(79,69,878)	(24,57,891)
(Increase)/Decrease in inventories	14,85,728	(3,66,67,296)
(Increase) in loans and advances & other non-current assets	(1,61,49,813)	(1,39,55,462)
Increase in trade payables, current liabilities and provisions	1,92,08,816	12,30,88,553
<b>Cash generated from operations</b>	<b>(41,55,57,887)</b>	<b>(18,64,44,018)</b>
Direct taxes paid (net of refunds)	(17,61,244)	(1,45,452)
<b>Net cash flow from operating activities</b>	<b>(41,73,19,131)</b>	<b>(18,65,89,470)</b>
<b>B. Cash flow from investing activities</b>		
Purchase of fixed assets	(5,68,14,764)	(31,11,45,110)
<b>Net cash (used in) investing activities</b>	<b>(5,68,14,764)</b>	<b>(31,11,45,110)</b>
<b>C. Cash flow from financing activities</b>		
Proceeds from issuance of preference share capital	24,05,00,000	19,50,00,000
Proceeds of long-term borrowings	23,00,00,000	26,50,00,000
Interest paid	(2,60,040)	(21,772)
<b>Net cash (used in) financing activities</b>	<b>47,02,39,960</b>	<b>45,99,78,228</b>
<b>Net (decrease) / increase in cash and cash equivalents (A+B+C)</b>	<b>(38,93,935)</b>	<b>(3,77,56,352)</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>2,67,18,371</b>	<b>6,44,74,723</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>2,28,24,436</b>	<b>2,67,18,371</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	15,31,534	10,82,108
Balance with scheduled banks:		
-in current accounts	2,12,92,902	2,56,36,263
<b>Cash &amp; Cash Equivalents in Cash Flow Statement:</b>	<b>2,28,24,436</b>	<b>2,67,18,371</b>

As per our report of even date


**For Bhagi Bhardwaj Gaur & Co.**


Chartered Accountants  
F.R No.: 007895N

  
**Mohit Gupta**  
Partner  
M. No. 528337

For and on behalf of the Board of Directors

  
**Eklavya Juneja**  
(Director)  
DIN:-06754247

  
**Sanjeev Vashistha**  
(Managing Director & CEO)  
DIN:-01457971

  
**Prabhat Singh**  
(Company Secretary)  
M. No:- FCS-8724

Place: New Delhi  
Date: 25-09-2019

Place: New Delhi  
Date: 25-09-2019



Pathkind Diagnostics Private Limited  
Notes to financial statements for the year ending March 31, 2019

**Note 1: Background**

Pathkind Diagnostics Private limited was incorporated on 6<sup>th</sup> October 2016 to engage in the business of running laboratories for carrying out pathological investigations of various branches of Bio-chemistry, Haematology, Histopathology, Microbiology, Electrophoresis, Immuno-Mistry, Immunology, Cytology, other pathological and radiological investigations.

**Note 2: Basis of Preparation**

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). The Company has prepared these financial statements to comply in all material respects with the notified under Section 133 of the Companies Act, 2013, read together with paragraph 7 of the Companies (accounts) Rules, 2014. The financial statements have been prepared on an accrual basis and under the historical cost convention.

These financial statements are presented in Indian Rupee(INR), which is the functional currency of the country.

**Significant Accounting Policies**

**(a) Use of estimates**

The preparation of financial statements in conformity with Indian GAAP which requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

**(b) Tangible Assets**

Fixed assets are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing fixed assets, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred. Fixed Assets under construction, advance paid towards the acquisition of fixed assets and cost of assets not put to use if any before the year end are disclosed as Capital Work-in-Progress.

**(c) Intangible Assets**

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired at purchase of business is recorded at their fair value as at the date of purchase of business. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Internally generated intangible assets, excluding capitalized development costs, are not capitalized and expenditure is reflected in the statement of profit and loss in the year in which the expenditure is incurred.



Pathkind Diagnostics Private Limited  
Notes to financial statements for the year ending March 31, 2019

**(d) Depreciation**

- I. Leasehold Improvements are depreciated over the useful life of the assets or the unexpired lease period, whichever is lower.
- II. Depreciation on all other fixed assets is provided using the Straight Line Method at the rates computed based on the estimated useful life of all assets as prescribed under the Schedule II of the Companies act, 2013 and estimated by the management.

The Company has considered following useful lives to provide depreciation on fixed assets:

<b>Tangible Assets</b>	<b>Useful Life (in years)</b>
Leasehold Improvements	6 - 9
Plant & Machinery	13
Office Equipments	5
Other Equipments	3
Computers / Servers	3 / 5
Furnitures & Fixtures	10
Vehicles – Cars	8
Low Value Assets	1

- III. Intangible assets are amortized using the straight line method over their useful lives as under:

<b>Intangible Assets</b>	<b>Useful Life (in years)</b>
Computer Software	4

**(e) Lease**

*Where the Company is lessee*

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.


**(f) Borrowing Costs**

Borrowing cost includes interest, amortization of ancillary costs incurred in connection with arrangement of borrowings.

Borrowing costs directly attributable to the acquisition, construction or production of an assets that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective assets. All other borrowing costs are expensed in the period they occur.

**(g) Impairment**

The Carrying Value of the assets are reviewed at each Balance sheet date to determine whether there is any indication of Impairment. If any, such indication exists, the recoverable amount of the assets is estimated. For assets that are not available for use, the recoverable amount is estimated at each Balance Sheet date. The recoverable is the highest of net selling price and its value in use. An Impairment loss is recognized whenever the carrying amount of an assets or its cash generating unit exceeds its recoverable amount. Impairment losses are recognized in the Profit & loss account. An Impairment loss is reversed if there has been a change in the estimates used to determine the





Pathkind Diagnostics Private Limited  
Notes to financial statements for the year ending March 31, 2019

recoverable amount. An Impairment loss is reversed only to the extent that the carrying amount of assets does not exceed the carrying amount that would have been determined net of depreciation or amortization, if no impairment loss had been recognized.

**(h) Cash and cash equivalents (for purpose of Cash Flow Statement)**

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

**(i) Cash flow statement**

Cash flows are reported using the indirect method, whereby profit before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

**(j) Inventories**

Inventories comprise of reagents, chemicals, surgical and laboratory supplies and stores and others are valued at lower of and net realizable value. Cost is determined on moving weighted average basis.

**(k) Revenue Recognition**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria is also met before revenue is recognized:

**i) Pathology services**

*-Laboratory Income*

Revenue comprises of amount billed (net of discounts) in respect of tests conducted and is recognized as and when the samples are registered for the purpose of conducting the tests.

*-Revenue from Collection Centers*

Revenue comprises of amount billed (net of Service Charge) in respect of tests conducted and is recognized as and when the samples are registered for the purpose of conducting the tests.

**ii) Sale of goods**

Sales are considered, net of returns and trade discounts, on transfer of significant risks and rewards of ownership to the buyer, which generally coincides with the delivery of goods to customers.

**iii) Income from other services**

Revenues from other services are recognized when services are rendered and related costs are incurred.

**(l) Foreign Exchange Transaction**


Foreign currency transactions and balances

(i) Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

(ii) Conversion

Foreign currency monetary items are retranslated using the exchange rate prevailing at the reporting date. Non-monetary items, which are measured in terms of historical cost denominated in a foreign currency, are reported using the exchange rate at the date of the transaction. Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency, are translated using the exchange rate at the date when such value was determined.



Pathkind Diagnostics Private Limited  
Notes to financial statements for the year ending March 31, 2019

(iii) Exchange Differences

Exchange differences arising on the settlement of monetary items or on reporting Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

**(m) Taxation**

Income tax expenses comprises current tax (i.e. the amount of the tax for the period determined in accordance with the income-tax Law) and deferred tax charge or credit (reflecting the tax effects of timing difference between accounting income & taxable income for the period). Income tax liability is ascertained on the basis of profit computed in accordance with the provisions of Income-Tax Act, 1961.

Deferred tax charge or credit reflect the tax effects of timing difference between accounting income & taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognized using the rates that have been enacted or substantively enacted by the Balance Sheet date. Deferred tax assets are recognized only to the extent there is a reasonable certainty that the assets can be realized in future. However, in case there is an unabsorbed depreciation or carried forward loss under taxation law, deferred tax assets are recognized only if there is virtual certainty of realization of such assets. Deferred tax assets are reviewed as at each Balance Sheet date and written down or written-up to reflect the amount that is reasonably/virtually (as case may be) to be realized. Deferred Tax Assets on unused tax losses are recognized only to the extent of net Deferred tax liabilities.

**(n) Retirement and other employee Benefits**

Retirement benefit in the form of provident fund is a defined contribution scheme. The contributions to the provident fund are charged to the statement of profit and loss for the year when the contributions are due.

The Company operates a defined benefit plans for its employees, viz., gratuity. The costs of providing benefits under this plan is determined on the basis of actuarial valuation at each year-end. Actuarial valuation is carried out for plan using the projected unit credit method. Actuarial gains and losses for defined benefit plan is recognized in full in the period in which they occur in the statement of profit and loss.



Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short-term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

**(o) Earnings Per Share**

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits / reverse share splits and bonus shares, as appropriate.

**(p) Provisions**

A provision is recognized when the Company has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.



# Pathkind Diagnostics Private Limited

Notes to financial statements for the year ending March 31, 2019

## (q) Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability during the year.

## (r) Segment reporting policy

The Company prepares its segment information in conformity with the accounting policies adopted for preparing and presenting the financial statements of the Company as a whole.





**Pathkind Diagnostics Private Limited**

Notes to financial statements for the year ended March 31, 2019

All amounts are in INR unless otherwise stated

3. Share capital	March 31, 2019	March 31, 2018
<b>Authorised</b>		
1,00,00,000 equity shares of Rs. 10 each (Previous year 1,00,00,000 equity shares of Rs. 10 each)	10,00,00,000	10,00,00,000
5,20,00,000 Preference share of Rs. 10 each (Previous year 2,20,00,000 Preference share of Rs. 10 each)	52,00,00,000	22,00,00,000
	<b>62,00,00,000</b>	<b>32,00,00,000</b>
<b>Issued, subscribed &amp; fully paid-up</b>		
1,00,00,000 equity shares of Rs. 10 each (Previous year 1,00,00,000 equity shares of Rs. 10 each)	10,00,00,000	10,00,00,000
4,15,25,000 Preference share of Rs. 10 each (Previous year 2,20,00,000 Preference share of Rs. 10 each)	41,52,50,000	22,00,00,000
	<b>51,52,50,000</b>	<b>32,00,00,000</b>

Notes :

(a) Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting year

*Equity shares*

	March 31, 2019		March 31, 2018	
	No. of shares	Amount	No. of shares	Amount
At the beginning of the year	1,00,00,000	10,00,00,000	1,00,00,000	10,00,00,000
Issued during the year	-	-	-	-
<b>Outstanding at the end of the year</b>	<b>1,00,00,000</b>	<b>10,00,00,000</b>	<b>1,00,00,000</b>	<b>10,00,00,000</b>

*Preference shares*

	March 31, 2019		March 31, 2018	
	No. of shares	Amount	No. of shares	Amount
At the beginning of the year	2,20,00,000	22,00,00,000	25,00,000	2,50,00,000
Issued during the year (refer note e below)	1,95,25,000	-	1,95,00,000	19,50,00,000
<b>Outstanding at the end of the year</b>	<b>4,15,25,000</b>	<b>22,00,00,000</b>	<b>2,20,00,000</b>	<b>22,00,00,000</b>

(b) Terms/ rights attached to equity shares

The Company has only one class of equity shares having par value of Rs. 10 per share. Each member holding equity shares therein shall have voting rights in proportion to the member's share of the paid up equity share capital. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the equity shareholders.

(c) Terms/ rights attached to preference shares

The Company has two class of preference shares having par value of Rs. 10 per share carrying a coupon rate of 0.1% per annum. The Company has issued 25,00,000 Optionally Convertible Preference Shares and 3,90,25,000 Compulsory Convertible Preference Shares as approved by the Shareholders in their respective meetings. The OCPS are redeemable/convertible and CCPS are only convertible into equity shares as per terms and conditions mentioned in the Securities Subscription Agreement dated 18th January, 2017. The CCPS shall always carry preference to any dividend and/ or distribution payable on equity shares and any other class of preference shares (including optionally convertible preference shares) but only after payment of interest on debentures. Preference shares shall not participate in the surplus funds, surplus assets and surplus profits on winding up, which may remain after entire capital has been repaid.



**Pathkind Diagnostics Private Limited**

Notes to financial statements for the year ended March 31, 2019

All amounts are in INR unless otherwise stated

**(d) Detail of shareholders holding more than 5% shares in the Company**

Name of the shareholder	March 31, 2019		March 31, 2019	
	No. of shares	% holding	No. of shares	% holding
<i>Equity shares of Rs. 10/- each fully paid</i>				
Mr. Arjun Juneja	35,02,200	35.02%	35,02,200	35.02%
Mr. Rajeev Juneja	29,63,400	29.63%	29,63,400	29.63%
Mr. Sheetal Arora	25,14,400	25.14%	25,14,400	25.14%
Mr. Sanjeev Vashishta	10,00,000	10.00%	10,00,000	10.00%
	<b>99,80,000</b>	<b>99.80%</b>	<b>99,80,000</b>	<b>99.80%</b>
<i>Optionally Convertible, non-participating preference shares of Rs. 10/- each fully paid</i>				
Beyondtime Consultants Private Limited	25,00,000	6.02%	25,00,000	11.36%
	<b>25,00,000</b>	<b>6.02%</b>	<b>25,00,000</b>	<b>11.36%</b>
<i>Compulsory Convertible, non-participating preference shares of Rs. 10/- each fully paid</i>				
Mr. Arjun Juneja	57,56,250	13.86%	8,75,000	3.98%
Mr. Rajeev Juneja	2,23,41,750	53.80%	1,31,65,000	59.84%
Mr. Sheetal Arora	1,09,27,000	26.31%	54,60,000	24.82%
	<b>3,90,25,000</b>	<b>93.98%</b>	<b>1,95,00,000</b>	<b>88.64%</b>

As per records of the Company, including its register of shareholders/ members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

(e) During the year, Company has issued 1,95,25,000 Compulsory Convertible Preference Shares (CCPS) having face value of Rs.10 per share on preferential allotment basis. 1,50,00,000 Compulsory Convertible Preference Shares having face value of Rs.10/- each were issued at par value. 45,25,000 Compulsory Convertible Preference Shares having face value of Rs.10/- each were issued at a premium of Rs.10/- each.



**Pathkind Diagnostics Private Limited**  
**Notes to financial statements for the year ended March 31, 2019**  
**All amounts are in INR unless otherwise stated**

4. Reserves and surplus	March 31, 2019	March 31, 2018
<b>Securities premium account</b>		
Balance at the beginning of the year	-	-
Addition on issue of Preference Shares (refer note 3(e))	4,52,50,000	-
<b>Balance at the end of year</b>	<b>4,52,50,000</b>	<b>-</b>
<b>Surplus in the statement of profit and loss</b>		
Balance as per the last financial statements	(29,69,19,992)	(92,097)
Profit/(loss) for the year	(46,70,01,554)	(29,68,27,895)
<b>Net surplus in the statement of profit and loss</b>	<b>(76,39,21,546)</b>	<b>(29,69,19,992)</b>
	<b>(71,86,71,546)</b>	<b>(29,69,19,992)</b>
5. Borrowings	March 31, 2019	March 31, 2018
<b>Non Current</b>		
<b>Unsecured Borrowings from related parties</b>		
0.1% Optionally Convertible Debentures (25,00,000 debenture of Rs 10 each, Previous year 25,00,000 debenture of Rs 10 each)	2,50,00,000	2,50,00,000
0.1% Compulsory Convertible Debentures (4,95,00,000 debenture of Rs 10 each, Previous year 2,65,00,000 debenture of Rs 10 each)	49,50,00,000	26,50,00,000
	<b>52,00,00,000</b>	<b>29,00,00,000</b>
6. Other Liabilities	March 31, 2019	March 31, 2018
<b>Non Current</b>		
Lease equilisation reserve	39,20,391	11,74,870
	<b>39,20,391</b>	<b>11,74,870</b>
<b>Current</b>		
Payable for Property, Plant & Equipment	39,85,601	62,80,015
Trade deposits	61,84,000	29,00,000
Advances from customers	4,35,59,858	2,46,45,916
Statutory dues payable	1,32,40,236	90,77,687
Interest accrued on debentures	5,68,475	1,48,989
	<b>6,75,38,170</b>	<b>4,30,52,607</b>
7. Provisions	March 31, 2019	March 31, 2018
<b>Non Current</b>		
<b>Provision for employee benefits</b>		
Provision for gratuity (refer note 25)	46,83,260	22,92,603
	<b>46,83,260</b>	<b>22,92,603</b>
<b>Current</b>		
<b>Provision for employee benefits</b>		
Provision for leave encashment	52,80,725	61,21,937
	<b>52,80,725</b>	<b>61,21,937</b>



**Pathkind Diagnostics Private Limited**  
**Notes to financial statements for the year ended March 31, 2019**  
**All amounts are in INR unless otherwise stated**

**8. Deferred Tax Liabilities (net)** **March 31, 2019** **March 31, 2018**

<b>Deferred tax balances</b>			
Deferred tax liabilities		55,86,164	42,15,980
Deferred tax assets		55,86,164	42,15,980
<b>Deferred tax liabilities (net)</b>		<b>-</b>	<b>-</b>

**Year ended 31 March 2019** **Opening Balance** **Recognised in Profit or loss** **Closing balance**

<b>Deferred tax liabilities in relation to</b>			
Property, plant and equipment	42,15,980	13,70,184	55,86,164
	<b>42,15,980</b>	<b>13,70,184</b>	<b>55,86,164</b>

<b>Deferred tax assets in relation to</b>			
Provision for employee benefits	22,15,617	8,59,639	30,75,256
Unclaimed Preliminary expenses	3,11,844	(77,961)	2,33,883
Unused tax losses	13,52,603	(1,64,567)	11,88,036
Lease equalisation reserve	3,05,466	7,13,835	10,19,301
Others	30,450	39,238	69,688
	<b>42,15,980</b>	<b>13,70,184</b>	<b>55,86,164</b>

<b>Deferred tax liabilities (net)</b>	<b>-</b>	<b>-</b>	<b>-</b>
---------------------------------------	----------	----------	----------

**Year ended 31 March 2018** **Opening Balance** **Recognised in Profit or loss** **Closing balance**

<b>Deferred tax liabilities in relation to</b>			
Property, plant and equipment	-	42,15,980	42,15,980
	<b>-</b>	<b>42,15,980</b>	<b>42,15,980</b>

<b>Deferred tax assets in relation to</b>			
Provision for employee benefits	-	22,15,617	22,15,617
Unclaimed Preliminary expenses	-	3,11,844	3,11,844
Unused tax losses	-	13,52,603	13,52,603
Lease equalisation reserve	-	3,05,466	3,05,466
Others	-	30,450	30,450
	<b>-</b>	<b>42,15,980</b>	<b>42,15,980</b>

<b>Deferred tax liabilities (net)</b>	<b>-</b>	<b>-</b>	<b>-</b>
---------------------------------------	----------	----------	----------

Deferred tax assets and liabilities are being offset as they relate to taxes on income levied by the same governing taxation laws.

**9. Trade Payables** **March 31, 2019** **March 31, 2018**

<b>Current</b>			
- total outstanding dues of micro and small enterprises (refer note no. 29)		42,04,328	20,61,755
'- total outstanding dues of creditors other than micro and small enterprises		6,83,33,377	8,19,22,591
		<b>7,25,37,705</b>	<b>8,39,84,346</b>





Pathkind Diagnostics Private Limited

Notes to financial statements for the year ended March 31, 2019

All amounts are in INR unless otherwise stated

10. Tangible Assets

	March 31, 2019							March 31, 2018	
Leasehold Improvements								12,40,55,069	12,73,66,600
Laboratory Equipments								9,47,20,329	9,49,16,455
Office Equipments								1,93,36,210	1,84,54,447
Other Equipments								27,37,708	40,55,080
Low Value Assets								-	1,55,529
Plant & machinery								2,41,10,736	1,84,76,814
Furniture & fixtures								2,58,33,285	2,66,54,447
Computers								1,77,72,118	2,58,33,285
Vehicles								59,90,167	1,91,34,157
								31,45,55,622	69,00,154
								31,61,13,683	31,61,13,683

Particulars	Leasehold Improvements	Laboratory Equipments	Office Equipments	Other Equipments	Low Value Assets	Plant & machinery	Furniture & fixtures	Computers	Vehicles	Total
<b>Gross block</b>										
As at 01.04.2017	14,24,05,029	9,97,48,933	2,05,06,488	14,175	49,88,435	6,12,457	1,91,95,082	2,83,18,206	5,60,201	5,74,376
Additions	63,34,798	-	2,05,06,488	-	-	6,12,457	1,91,95,082	2,83,18,206	2,21,97,912	34,56,35,589
Deletions	13,60,70,231	9,97,48,933	2,05,20,663	49,88,435	6,12,457	1,91,95,082	2,83,18,206	2,27,58,113	76,63,047	33,98,75,167
As at 31.03.2018	1,55,39,994	73,85,762	52,98,001	2,75,627	8,07,436	70,62,387	23,24,669	59,73,995	-	4,46,67,871
Additions *	34,35,477	-	-	-	-	-	-	-	-	34,35,477
Deletions *	14,81,74,748	10,71,34,695	2,58,18,664	52,64,062	14,19,893	2,62,57,469	3,06,42,875	2,87,32,108	76,63,047	38,11,07,561
As at 31.03.2019	14,81,74,748	10,71,34,695	2,58,18,664	52,64,062	14,19,893	2,62,57,469	3,06,42,875	2,87,32,108	76,63,047	38,11,07,561
<b>Accumulated Depreciation</b>										
As at 01.04.2017	-	-	709	-	-	-	-	31,812	-	32,521
Depreciation for the year	87,03,631	48,32,478	20,65,507	9,33,355	4,56,928	7,18,268	16,63,759	35,92,144	7,62,893	2,37,28,963
Deletions / Adjustments	87,03,631	48,32,478	20,66,216	9,33,355	4,56,928	7,18,268	16,63,759	36,23,956	7,62,893	2,37,61,484
As at 31.03.2018	1,54,16,048	75,81,888	44,16,238	15,92,999	9,62,965	14,28,465	31,45,831	73,36,034	9,09,987	4,27,90,454
Depreciation for the year	-	-	-	-	-	-	-	-	-	-
Deletions / Adjustments	2,41,19,679	1,24,14,366	64,82,454	25,26,354	14,19,893	21,46,733	48,09,590	1,09,59,990	16,72,880	6,65,51,939
As at 31.03.2019	12,73,66,600	9,49,16,455	1,84,54,447	40,55,080	1,55,529	1,84,76,814	2,66,54,447	1,91,34,157	69,00,154	31,61,13,683
Net Block	12,40,55,069	9,47,20,329	1,93,36,210	27,37,708	-	2,41,10,736	2,58,33,285	1,77,72,118	59,90,167	31,45,55,622

\* Note:

During the year, the company has written off leasehold improvement of Rs. 34,35,477/- incurred for setting up pathology lab in Agra as the Uttar Pradesh State Pollution Control Board (UPSPCB) refused to issue No Objection Certificate / BioMedical Waste registration to the Company in view of the "ad hoc moratorium" imposed by the Hon'ble Supreme Court on setting up of new industries and expansion of old industries in the Taj Trapezium Zone.



**Pathkind Diagnostics Private Limited**

Notes to financial statements for the year ended March 31, 2019

All amounts are in INR unless otherwise stated

<b>11. Intangible Assets</b>	<b>March 31, 2019</b>	<b>March 31, 2018</b>
Computer Software	2,23,98,850	2,18,10,030
	<b>2,23,98,850</b>	<b>2,18,10,030</b>
<b>Particulars</b>	<b>Computer Software</b>	<b>Total</b>
<b>Gross block</b>		
As at 01.04.2017	-	-
Additions	3,04,52,231	3,04,52,231
Deletions	-	-
<b>As at 31.03.2018</b>	<b>3,04,52,231</b>	<b>3,04,52,231</b>
Additions	85,52,176	85,52,176
Deletions	-	-
<b>As at 31.03.2019</b>	<b>3,90,04,407</b>	<b>3,90,04,407</b>
<b>Accumulated Amortization</b>		
As at 01.04.2017	-	-
Depreciation for the year	86,42,201	86,42,201
Deletions / Adjustments	-	-
<b>As at 31.03.2018</b>	<b>86,42,201</b>	<b>86,42,201</b>
Depreciation for the year	79,63,356	79,63,356
Deletions / Adjustments	-	-
<b>As at 31.03.2019</b>	<b>1,66,05,557</b>	<b>1,66,05,557</b>
<b>Net block</b>		
As at 31.03.2018	2,18,10,030	2,18,10,030
<b>As at 31.03.2019</b>	<b>2,23,98,850</b>	<b>2,23,98,850</b>



**Pathkind Diagnostics Private Limited**

Notes to financial statements for the year ended March 31, 2019

All amounts are in INR unless otherwise stated

	March 31, 2019	March 31, 2018
<b>12. Loans and advances</b>		
<b>Non Current</b>		
Capital advances	20,91,502	7,91,199
Trade / security deposits	1,74,46,566	94,74,620
Loan and advances to related parties (refer note 31)	3,00,00,000	3,00,00,000
Loans and advances to Others	37,500	-
<b>Total</b>	<b>4,95,75,568</b>	<b>4,02,65,819</b>
<b>Current</b>		
Advance to suppliers	20,46,989	19,23,448
Advances to employees	31,07,522	17,08,098
Prepaid expenses	34,45,184	11,22,517
Balances with government authorities	50,06,001	7,73,766
Loans and advances to Others	62,500	-
<b>Total</b>	<b>1,36,68,196</b>	<b>55,27,829</b>
<b>13. Other assets</b>	<b>March 31, 2019</b>	<b>March 31, 2018</b>
<b>Non Current</b>		
Advance income tax (net of provision)	19,06,696	1,45,452
<b>Total</b>	<b>19,06,696</b>	<b>1,45,452</b>
<b>14. Inventories</b>	<b>March 31, 2019</b>	<b>March 31, 2018</b>
<b>In hand</b>		
Reagents, chemicals, surgicals and laboratory supplies	3,51,81,568	3,66,67,296
<b>Total</b>	<b>3,51,81,568</b>	<b>3,66,67,296</b>
<b>15. Trade receivables</b>	<b>March 31, 2019</b>	<b>March 31, 2018</b>
<b>Unsecured, considered good unless stated otherwise</b>		
Outstanding for a period exceeding six months from the date they are due for payment	-	-
<b>Total</b>	<b>-</b>	<b>-</b>
Outstanding for a period less than six months from the date they are due for payment	1,04,27,769	24,57,891
<b>Total</b>	<b>1,04,27,769</b>	<b>24,57,891</b>
<b>16. Cash and bank balances</b>	<b>March 31, 2019</b>	<b>March 31, 2018</b>
<b>Cash and cash equivalents</b>		
Balance with banks in current accounts	2,12,92,902	2,56,36,263
Cash in hand	15,31,534	10,82,108
<b>Total</b>	<b>2,28,24,436</b>	<b>2,67,18,371</b>



**Pathkind Diagnostics Private Limited**

Notes to financial statements for the year ended March 31, 2019

All amounts are in INR unless otherwise stated

	March 31, 2019	March 31, 2018
<b>17. Revenue from operations</b>		
Sale of pathology services	29,81,98,229	4,45,47,855
Sale of products	1,60,77,396	13,06,846
Sale of clinical trial services	3,00,000	-
Sale of scrap	38,452	2,000
<b>Revenue from operations (net)</b>	<b>31,46,14,077</b>	<b>4,58,56,701</b>
<b>18. Other income</b>		
Net gain on foreign exchange fluctuation	-	1,29,266
	-	<b>1,29,266</b>
<b>19. Cost of reagents, chemicals, surgicals and laboratory supplies consumed</b>		
Inventories at the beginning of the year	3,66,67,296	-
Add : Purchases during the year	13,17,04,859	7,99,60,028
	16,83,72,155	7,99,60,028
Less : Inventories at the end of the year	3,51,81,568	3,66,67,296
<b>Cost of reagents, chemicals, surgicals and laboratory supplies consumed</b>	<b>13,31,90,587</b>	<b>4,32,92,732</b>
<b>20. Employee benefits expenses</b>		
Salaries, wages and bonus	25,78,90,931	12,46,55,140
Contribution to provident and other funds	1,22,11,087	55,79,544
Gratuity expense (refer note 25)	23,90,657	20,91,457
Staff welfare expenses	74,41,629	32,92,790
	<b>27,99,34,304</b>	<b>13,56,18,931</b>
<b>21. Depreciation and amortisation expense</b>		
Depreciation of tangible assets	4,27,90,455	2,37,28,963
Amortisation of intangible assets	79,63,356	86,42,201
	<b>5,07,53,811</b>	<b>3,23,71,164</b>
<b>22. Finance costs</b>		
Interest expense on:		
- debentures	4,66,095	1,48,989
- others	2,13,431	21,772
	<b>6,79,526</b>	<b>1,70,761</b>





**Pathkind Diagnostics Private Limited**

**Notes to financial statements for the year ended March 31, 2019**

**All amounts are in INR unless otherwise stated**

<b>23. Other expenses</b>	<b>March 31, 2019</b>	<b>March 31, 2018</b>
Electricity and water charges	1,50,41,151	44,58,942
Rent	4,79,99,026	2,21,61,824
Rates and taxes	44,47,530	10,00,548
Insurance	11,66,362	5,20,542
Repairs and maintenance		
- Building	15,86,232	16,41,546
- Plant and machinery	6,54,524	8,80,940
- Others	47,17,384	11,46,706
Advertisement and sales promotion	6,37,07,490	2,03,07,283
Travelling and conveyance	3,40,61,054	1,79,33,182
Vehicle running and maintenance	1,12,049	43,636
Postage and courier	4,04,57,662	1,16,62,435
Communication cost	54,92,163	30,60,765
Retainership expenses	92,03,122	65,32,911
Printing and stationary	71,74,202	28,66,385
Service charge to collection centres	1,63,31,586	6,21,369
Legal and professional charges	37,94,364	13,83,172
Cloud services and website expenses	98,29,934	79,02,089
Laboratory test charges	56,27,533	14,80,402
Payment to auditors (refer details below)	2,36,000	2,41,400
Staff hiring and training charges	65,96,051	1,19,65,894
Preliminary expense written off	-	14,99,250
Prior period expenses	28,77,025	4,87,593
Fixed assets written off	34,35,477	63,34,798
Miscellaneous expenses	1,74,85,288	52,26,662
	<b>30,20,33,209</b>	<b>13,13,60,274</b>

<b>Payment to auditors</b>	<b>March 31, 2019</b>	<b>March 31, 2018</b>
As auditor:		
Audit fees	1,77,000	1,82,400
Tax audit fees	59,000	59,000
	<b>2,36,000</b>	<b>2,41,400</b>

**24. Earnings per share (EPS)**

Basic earnings per equity share has been computed by dividing net profit after tax by the weighted average number of equity shares outstanding for the year. Diluted earnings per equity share has been computed using the weighted average number of equity shares and dilutive potential equity shares outstanding during the year.

	<b>March 31, 2019</b>	<b>March 31, 2018</b>
Net Profit after tax	(46,70,01,554)	(29,68,27,895)
Weighted average number of equity shares outstanding during the year	1,00,00,000	1,00,00,000
Nominal value of equity share	10,00,00,000	10,00,00,000
Basic EPS per share	(46.70)	(29.68)
Diluted EPS per share	(46.70)	(29.68)

1. Basic and Diluted EPS have been calculated only considering the number of Equity shares.

2. Non-participating optionally convertible preference shares, non-participating compulsory convertible preference shares, optionally convertible debentures and compulsory convertible debentures that could potentially dilute basic earnings per share in the future have not been included in the calculation of diluted earnings per share because they are antidilutive for the year ended March 31, 2019 and March 31, 2018.



**25. Employment benefits :-**

**(a) Defined contribution plan**

The Company makes Provident Fund and Employees State Insurance Scheme contribution which are defined contribution plans. Under the scheme the company is required to contribute a specified percentage of the payroll to fund the benefits. The company has recognised Rs. 1,21,75,327/- (Previous year March 31, 2018 Rs.55,62,357/-) and Rs. 22,74,837/- (Previous year March 31, 2018 Rs.7,61,294) towards contribution to provident fund & employees state insurance scheme respectively in the profit & loss for the year ended March 31, 2019. The contribution payable to these plans by the company are at the rates specified in the rules of the scheme.

**(b) Defined benefit plan**

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service or part thereof in excess of six months.

The following tables summarise the components of net benefit expense recognized in the statement of profit and loss and amounts recognized in the balance sheet for the gratuity plan.

**Statement of profit and loss**

Net employee benefit expense recognized in employee cost:

	March 31, 2019	March 31, 2018
Current service cost	32,12,196	21,52,163
Interest cost on benefit obligation	1,78,823	15,689
Net actuarial (gain) / loss recognized in the year	(10,00,362)	(76,395)
Net benefit expense	<u>23,90,657</u>	<u>20,91,457</u>

**Balance Sheet**

Benefit Asset / Liability

	March 31, 2019	March 31, 2018
Present value of defined benefit obligation	46,83,260	22,92,603
Plan (liability)	<u>46,83,260</u>	<u>22,92,603</u>

**Change in present value of the defined benefit obligation are as follows:**

	March 31, 2019	March 31, 2018
Opening defined benefit obligation	22,92,603	2,01,146
Current service cost	32,12,196	21,52,163
Interest cost	1,78,823	15,689
Actuarial (gain) / loss	(10,00,362)	(76,395)
Closing defined benefit obligation	<u>46,83,260</u>	<u>22,92,603</u>

**The principal assumptions used in determining gratuity obligations for the Company's plans are shown below:**

	March 31, 2019	March 31, 2018
	(%)	(%)
Discount rate	7.66	7.80
Increase in compensation cost	9.00	9.00
Employee turnover	8.00	8.00

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.



**26. Segment Information**

**a. Basis of Segmentation**

The operation of the company are limited to one segment, viz. running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Cytology, other pathological investigations which is considered the only reportable segment as per AS-17.

**b. Geographical Segment**

The company operates only in one country and does not have any separate identifiable geographic segment.

**c. Major customer**

No single customer has accounted for more than 10% of the company's revenue for the year ended March 31, 2019.

**27. Contingent Liabilities**

The Company doesn't foresee any liability arising in future on account of any litigation/event not accounted for.

**28. Capital & other commitments**

(i) Estimated amounts of contracts remaining to be executed on capital account & not provided for is Rs. 38,60,548/- (previous year Rs.32,78,248/-)

(ii) The Company has also entered into other commitments for purchase order of reagents and chemicals which are issued only after considering the requirements per operating cycle for sale of service. Such commitments have been entered in lieu of machineries costs and the values of such commitments is not quantifiable.

**29. Details of dues to Micro and Small Enterprises as per Micro, Small and Medium Enterprise Development (MSMED) Act, 2006**

Particulars	March 31, 2019	March 31, 2018
1. The principal amount and remaining unpaid to any supplier as at the end of accounting period.	42,04,328	20,61,755
2. Interest due thereon remaining unpaid to any supplier as at the end of accounting period.	Nil	Nil
3. The amount of interest paid by the buyer in terms of Section 16, of the Micro Small and Medium Enterprise Development Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting period.	Nil	Nil
4. The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under Micro Small and Medium Enterprise Development Act, 2006.	Nil	Nil
5. The amount of interest accrued and remaining unpaid at the end of each accounting period; and	Nil	Nil
6. The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under Section 23 of the Micro Small and Medium Enterprise Development Act, 2006.	Nil	Nil

**30. Assets taken on operating leases**

The Company has taken the offices/labs at various locations under operating lease agreements, These are generally cancelled at the option of the company & are renewed by the mutual consent on mutually agreed terms. The lease payments recognised in the profit & loss for the year ended March 31, 2019 is Rs. 4,52,53,505/- (Previous year March 31, 2018 Rs.2,09,86,954/-)

Below is the disclosure & future minimum lease payments :-

Particulars	March 31, 2019	March 31, 2018
Within one year	4,07,44,062	1,72,95,000
After one year but not more than five years	18,43,63,019	7,60,15,154
More than five years	15,01,08,398	7,88,97,421



**31. Related party disclosures**

List of related parties and relationships with whom transactions have taken place during the year

---

**i. List of related parties**

Key Management Personnel (KMP)

Mr. Rajeev Juneja  
Mr. Arjun Juneja  
Mr. Sheetal Arora  
Mr. Sanjeev Vashishta  
Mr. Eklavya Juneja

Enterprises on which KMP exercise significant influence

Mankind Pharma Limited  
Mankind Biosys Private Limited  
Beyondtime Consultants Private Limited  
A S Packers  
Teen Murti Product Private Limited  
Rashi Apparels Private Limited  
J K Print Pack  
Mankind Specialities  
N S Industries  
Pharma Force Lab  
Paonta Process Equipment  
Lifestar Pharma Private Limited  
Magnet Labs Private Limited  
Copmed Pharmaceuticals Private Limited  
Mediforce Healthcare Private Limited  
Sirmour Remedies Private Limited  
Relax Pharmaceuticals Private Limited  
Vetbesta Labs  
Medipack Innovations Private Limited  
Pharma Pet  
A To Z Packers





**Pathkind Diagnostics Private Limited**  
**Notes to financial statements for the year ended March 31, 2019**  
**All amounts are in INR unless otherwise stated**

**ii. Transactions occurred during the year**

Particulars	KMP		Enterprises over which KMP exercise significant influence	
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
<b>A. Sale of services</b>				
Mankind Pharma Limited	-	-	4,88,000	4,24,405
A S Packers	-	-	4,500	4,250
J K Print Pack	-	-	1,23,500	82,450
Mankind Specialities	-	-	12,500	9,775
N S Industries	-	-	2,500	5,100
Pharma Force Lab	-	-	1,53,000	1,23,250
Paonta Process Equipment	-	-	2,000	1,700
Copmed Pharmaceuticals Private Limited	-	-	1,43,500	1,12,200
Mediforce Healthcare Private Limited	-	-	1,09,500	64,600
Sirmour Remedies Private Limited	-	-	76,000	76,500
Relax Pharmaceuticals Private Limited	-	-	98,000	87,125
Vetbesta Labs	-	-	31,000	21,675
Medipack Innovations Private Limited	-	-	40,500	850
Pharma Pet	-	-	8,000	1,275
A To Z Packers	-	-	40,500	-
	<u>-</u>	<u>-</u>	<u>13,33,000</u>	<u>10,15,155</u>
<b>B. Purchase of goods (net)</b>				
Mankind Pharma Limited	-	-	1,54,759	18,413
A S Packers	-	-	1,16,81,118	68,50,989
	<u>-</u>	<u>-</u>	<u>1,18,35,877</u>	<u>68,69,402</u>
<b>C. Purchase of services</b>				
Mankind Pharma Limited	-	-	59,966	-
Teen Murti Product Private Limited. (Blue Stone GZB)	-	-	-	54,40,620
Rashi Apparels Private Limited (Zip Hotel Nehru Place)	-	-	-	4,05,899
Broadway Hospitality Services Pvt Ltd (Central Blue Stone-GGN)	-	-	-	2,84,583
	<u>-</u>	<u>-</u>	<u>59,966</u>	<u>61,31,102</u>
<b>D. Rent expense</b>				
Mankind Pharma Limited	-	-	96,32,449	1,03,73,404
Mankind Biosys Private Limited	-	-	97,80,636	-
	<u>-</u>	<u>-</u>	<u>1,94,13,085</u>	<u>1,03,73,404</u>
<b>E. Reimbursements made</b>				
Mankind Pharma Limited	-	-	-	3,82,24,327
Lifestar Pharma Private Limited	-	-	-	92,549
Mankind Biosys Private Limited	-	-	9,01,685	-
Mr. Sanjeev Vashishta	10,27,343	-	-	-
Mr. Eklavaya Juneja	52,072	-	-	-
	<u>10,79,415</u>	<u>-</u>	<u>9,01,685</u>	<u>3,83,16,876</u>
<b>F. Security deposits paid</b>				
Mankind Pharma Limited	-	-	-	37,67,580
Mankind Biosys Private Limited	-	-	82,88,676	-
	<u>-</u>	<u>-</u>	<u>82,88,676</u>	<u>37,67,580</u>
<b>G. Remuneration paid</b>				
Mr. Sanjeev Vashishta	3,12,36,667	3,05,87,278	-	-
	<u>3,12,36,667</u>	<u>3,05,87,278</u>	<u>-</u>	<u>-</u>
<b>H. Issue of debentures</b>				
(2,30,00,000 0.1% Compulsory Convertible Debentures (previous year 2,65,00,000 0.1% Compulsory Convertible Debentures))				
Mr. Arjun Juneja	5,75,00,000	9,35,50,000	-	-
Mr. Rajeev Juneja	10,81,00,000	9,72,50,000	-	-
Mr. Sheetal Arora	6,44,00,000	7,42,00,000	-	-
	<u>23,00,00,000</u>	<u>26,50,00,000</u>	<u>-</u>	<u>-</u>



**Pathkind Diagnostics Private Limited**  
**Notes to financial statements for the year ended March 31, 2019**  
**All amounts are in INR unless otherwise stated**

**iii. Balances outstanding as at the year end**

Particulars	KMP		Enterprises over which KMP exercise significant influence	
	As at March 31, 2019	As at March 31, 2018	As at March 31, 2019	As at March 31, 2018
<b>A. Trade receivables</b>				
Mankind Pharma Limited	-	-	4,000	4,24,405
A. S. Packers	-	-	-	4,250
J.K Print Pack	-	-	-	82,450
Mankind Specialities	-	-	-	9,775
N.S. Industries	-	-	100	5,100
Pharma Force Lab	-	-	-	1,23,250
Paonta Process Equipment	-	-	-	1,700
Copmed Pharmaceuticals Private Limited	-	-	2,550	1,12,200
Mediforce Healthcare Private Limited	-	-	12,825	64,600
Sirmour Remedies Private Limited	-	-	-	76,500
Relax Pharmaceuticals Private Limited	-	-	-	87,125
Vetbesta Labs	-	-	-	21,675
Medipack Innovations Private Limited	-	-	-	850
Pharma Pet	-	-	-	1,275
			<b>19,475</b>	<b>10,15,155</b>
<b>B. Trade payables</b>				
A. S. Packers	-	-	18,41,477	13,20,889
Brodway Hospitality P Ltd (Central Blue Stone Hotel Gurgaon)	-	-	-	26,564
Teen Murti Product Private Limited.	-	-	-	5,32,574
			<b>18,41,477</b>	<b>18,80,027</b>
<b>C. Remuneration payable to KMP</b>				
Mr. Sanjeev Vashishta	-	15,53,478	-	-
	-	<b>15,53,478</b>	-	-
<b>D. Loans and advances to related parties include</b>				
Mr. Sanjeev Vashishta	3,00,00,000	3,00,00,000	-	-
	<b>3,00,00,000</b>	<b>3,00,00,000</b>	-	-
<b>E. 0.1% Optionally Convertible Debentures</b>				
Beyondtime Consultants Private Limited	-	-	2,50,00,000	2,50,00,000
	-	-	<b>2,50,00,000</b>	<b>2,50,00,000</b>
<b>F. 0.1% Compulsory Convertible Debentures</b>				
Mr. Arjun Juneja	15,10,50,000	9,35,50,000	-	-
Mr. Rajeev Juneja	20,53,50,000	9,72,50,000	-	-
Mr. Sheetal Arora	13,86,00,000	7,42,00,000	-	-
	<b>49,50,00,000</b>	<b>26,50,00,000</b>	-	-





**Pathkind Diagnostics Private Limited**  
**Notes to financial statements for the year ended March 31, 2019**  
**All amounts are in INR unless otherwise stated**


---

32. There were no amounts which were required to be transferred to Investors Education and Protection Fund.
33. Previous year figures have been regrouped/ rearranged wherever necessary to conform to current year's classification.

For and on behalf of the Board of Directors

  
**Eklavya Juneja**  
(Director)  
DIN:-06754247

  
**Sanjeev Vashistha**  
(Managing Director & CEO)  
DIN:-01457971

  
**Prabhat Singh**  
(Company Secretary)  
M. No:- FCS-8724

